PRESS LIVE with Nuvilex (NVLX) a Small Sector Report from Wall-Street.com

Nuvilex has released press that poise it to be an industry leader in the Pancreatic Cancer Treatment Sector.

Nuvilex's mission has been and continues to be to develop, manufacture, and market products that are "Good for You, Good for the Environment."

Nuvilex is a cutting edge, innovative Company whose aim is to initiate a paradigm shift, generating revenue at the same time as creating cancer and other cell related solutions to treat important human diseases, such as pancreatic cancer while retaining our connections to natural products. The present effort underway will give rise to dramatic advances in cancer therapy and benefit millions of people worldwide.

All of our products have been, and will continue to be, developed through the use of natural products and/or biotechnology in order to assist people in the pursuit of a healthy body and to improve the environment around us all. We invite you to learn more about Nuvilex and our products and plans.

NeuroMetrix Distribution Agreement with One Source Medical Group for Sensus Pain Management

NeuroMetrix, Inc. (Nasdaq: NURO), a medical device company focused on the diagnosis and treatment of the neurological complications of diabetes, today announced the signing of a distribution agreement with OneSource Medical Group, LLC (OSMG) of Clearwater, Florida for its SENSUS™ pain management device. OneSource Medical Group concentrates its sales efforts in the south east and south central United States. Its primary focus is diabetes testing supplies and it also covers pain management products and urological supplies.

Small Sector Report - Diabetic Neuropathy Treatment Market

Diabetes is a chronic disease in which there are high levels of sugar in the blood. The World Diabetes Foundation estimates that there will be 438 million people with diabetes by the year 2030. The global market for products in the management of diabetes currently stands at $41 billion and is on pace to grow to over $114 billion by 2018. Oral anti-diabetics were the leading category of drugs in 2010 and showed a growth rate of 6.3% from the total global sales. The total sales for insulin products increased significantly as well.

Anti-diabetic products include glucose meters, lancets, test strips, continuous blood glucose meters, insulin, insulin pumps, syringes and other insulin delivery devices and anti-diabetic drugs. The bulk of product revenues come from three segments - test strips, insulin and anti-diabetic drugs - which will remain the largest sources of product revenues over the next ten years. The most significant growth, however, will come from the nascent segment of continuous blood glucose monitors, which provide significantly added clinical benefit at only a modestly higher cost compared to standard blood glucose meters.

Top players in the global diabetes market are Novo Nordisk, Eli Lilly, Merck & Co., amongst others. Currently, the US remains the single largest source of product revenues in diabetes management, at roughly 37% of the global market, but that percentage is expected to drop to 28% by 2018, primarily as a result of significant growth in the Asia-Pacific region.

Small Sector Report - TONIX Poster Presentation

TONIX Pharmaceuticals Announces Poster Presentation at the 2012 American College of Rheumatology Annual Scientific Meeting. Tonix Pharmaceuticals Holding Corp is a specialty pharmaceutical company developing non-addictive treatments for chronic pain syndromes. Today they announced the on-line publication of the abstract of preclinical and human pharmacokinetic data related to the Company's fibromyalgia and post-traumatic stress disorder programs. It will present theses findings at the 2012 American Co llege of Rheumatology held from November 10-14, at the Walter E. Washington Convention Center in Washington, D.C.

Fibromyalgia is a common and complex central nervous system condition characterized by chronic diffuse musculoskeletal pain, increased pain sensitivity at multiple tender points, fatigue, abnormal pain processing, and disturbed sleep. This often features psychological stress. Despite the fact that most patients suffer from poor sleep, there are no medications indicated for FM that work by improving sleep quality. Research has shown that the restorative sleep of patients is disrupted by alarm signals called CAP A2 and A3. In a Phase 2a trial, TONIX demonstrated that bedtime administration of very low dose cyclobenzaprine improves core FM symptoms including pain, tenderness, fatigue, and depression, and also demonstrated that improvements in key symptoms correlate with increased nights of restorative sleep.

TONIX is developing innovative prescription medications for challenging disorders of the central nervous system. The company targets conditions characterized by significant unmet medical need, inadequate existing treatment options, and high dissatisfaction among both patients and physicians. TONIX's core technology improves the quality of sleep in patients with chronic pain syndromes. TONIX's lead product is designed to be a fundamental advance in sleep hygiene and pain management and to be safer and more effective than currently available treatments. Its most advanced product candidate, TNX-102 SL for FM and post-traumatic stress disorder, is a novel dosage formulation of cyclobenzaprine.

PressLive - Tonix Pharmaceuticals Health Canada Clearance to Study Treatment for Fibromyalgia

NEW YORK, Jun 27, 2012 (BUSINESS WIRE) -- Tonix Pharmaceuticals Holding Corp. TNXP -1.00% ("TONIX" or the "Company"), a specialty pharmaceutical company developing therapies for challenging disorders of the central nervous system ("CNS") including fibromyalgia syndrome ("FM") and post-traumatic stress disorder ("PTSD"), announces that the Company will initiate a comparative study on a novel treatment for FM that targets sleep problems associated with chronic pain syndromes. TONIX's new approach is opiate-free and non-addictive. Health Canada has provided TONIX with clearance for a comparative pharmacokinetic ("PK") and bioavailability ("BA") study of TNX-102, the Company's novel oral formulation of cyclobenzaprine for the treatment of FM. Health Canada has issued a No Objection Letter to TONIX's Clinical Trial Application. Cyclobenzaprine is the active ingredient in two U.S. FDA- and Health Canada-approved prescription muscle relaxants that are marketed by other companies. Seth Lederman, M.D., Chairman and President of TONIX said, "FM patients are desperate to get a good night's sleep because many have learned that restorative sleep can improve their pain and fatigue. We have designed TNX-102 to work at night after bedtime administration. We expect the results of this PK study will corroborate studies done in animals, and we will use the findings to finalize our commercial formulation for pivotal clinical studies." Dr. Lederman also said, "The objective of this study is to compare the PK profile of our proprietary TNX-102 formulation with the PK of a conventional immediate release formulation and the PK of an intravenous injection." In addition, Dr. Lederman noted, "Immediate release cyclobenzaprine results in relatively steady blood levels over the course of the day, which is ideal for the treatment of muscle spasms, its approved indication. In our Phase 2a study, bedtime administration of very low dose cyclobenzaprine capsules improved core FM symptoms including pain, tenderness, fatigue and depression. This study also demonstrated that those improvements were correlated with increased nights of restorative sleep. Our goal is to develop a bedtime cyclobenzaprine treatment with more predictable beneficial effects and reduced next-day somnolence compared with the current doses and formulations of cyclobenzaprine." The study will be conducted in Canada by a leading global clinical research organization. TONIX anticipates the clinical portion of the study to be completed by the end of July, with analysis of the subjects' blood samples to be completed before September 30, 2012. TONIX's comparative PK/BA study is expected to enroll approximately 15 healthy adult volunteers to participate in a single-dose, open-label, randomized study. The three arms will compare a TNX-102 candidate tablet in a novel formulation containing a very low dose (2.4 mg) of cyclobenzaprine with a currently available, immediate release, 5 milligram cyclobenzaprine tablet and with intravenous cyclobenzaprine, which is considered a standard for BA studies. The study will measure each subject's circulating blood levels of cyclobenzaprine over time in each condition. TONIX also plans to use new doses and formulations of cyclobenzaprine in a new treatment for PTSD, in addition to FM.

OpenCEOLive - Tonix Pharmaceuticals CEO Seth LedermanTalks Importance of Fibromyalgia

The Company's lead programs are potential new treatments for fibromyalgia and post-traumatic stress disorder, which are chronic CNS syndromes. In each of these programs, TONIX seeks to use new doses and formulations of cyclobenzaprine in new treatment regimens. Cyclobenzaprine is the active ingredient of two prescription muscle relaxants that have been approved by the U.S. Food and Drug Administration (FDA) and are marketed by other companies.